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Background. Although norovirus is the most common cause of gastroenteritis, there are few data on the com-
munity incidence of infection/disease or the patterns of acquired immunity or innate resistance to norovirus.
Methods. We followed a community-based birth cohort of 194 children in Ecuador with the aim to estimate
(1) the incidence of norovirus gastroenteritis from birth to age 3 years, (2) the protective effect of norovirus infection
against subsequent infection/disease, and (3) the association of infection and disease with FUT2 secretor status.
Results. Over the 3-year period, we detected a mean of 2.26 diarrheal episodes per child (range, 0–12 episodes).
Norovirus was detected in 260 samples (18%) but was not found more frequently in diarrheal samples (79 of 438
[18%]), compared with diarrhea-free samples (181 of 1016 [18%]; P = .919). A total of 66% of children had at least 1
norovirus infection during the ﬁrst 3 years of life, and 40% of children had 2 infections. Previous norovirus infections
were not associated with the risk of subsequent infection. All genogroup II, genotype 4 (GII.4) infections were among
secretor-positive children (P < .001), but higher rates of non-GII.4 infections were found in secretor-negative child-
ren (relative risk, 0.56; P = .029).
Conclusions. GII.4 infections were uniquely detected in secretor-positive children, while non-GII.4 infections
were more often found in secretor-negative children.
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Norovirus is increasingly recognized as the most com-
mon etiology of diarrheal disease in all age groups and
the second most common cause of severe disease in
young children. Norovirus is associated with approxi-
mately 18% of gastroenteritis cases worldwide, and
this proportion is similar across the age range [1]. In
some developed countries, including the United States,
where infant vaccination has reduced the incidence of
rotavirus gastroenteritis, norovirus remains the most
common cause of pediatric gastroenteritis in patients
brought to medical care [2].
Noroviruses are a genetically diverse group of
single-stranded RNA viruses and can be divided into
genogroups, of which viruses from genogroup I (GI),
genogroup II (GII), and genogroup IV (GIV) infect
humans. Immunity is not lifelong, as infection, reinfec-
tion, and disease occur throughout life. Challenge stud-
ies conducted since the 1970s have indicated that
protection against infection and disease is primarily
against the same genotype [3]. A recent birth cohort
study of Peruvian children conﬁrmed this, as GII infec-
tions were protective against subsequent GII infection
and disease and reinfection with the same genotype
was uncommon [4].
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In addition to acquired immunity, there is also a human
genetic component to norovirus susceptibility. Noroviruses
use glycans of the ABH and Lewis histo-blood group antigen
(HBGA) family for attachment to their target cells [5]. Express-
ion of HBGAs is catalyzed by α1,2 fucosyltransferase encoded
by the gene encoding α(1,2) fucosyltransferase (FUT2). Indivi-
duals with ≥1 functional FUT2 allele and, thus expression of
FUT2 enzyme are called secretor-positive individuals. Homozy-
gous individuals with a nonsense mutation (FUT2−/−) are
called secretor-negative individuals and represent up to 20%
of the European population [6]. Most data on susceptibility to
norovirus infection pertain to the prototype Norwalk strain
(GI, genotype 1 [GI.1]) used in challenge studies, with limited
observational data demonstrating that expression of HBGAs is
associated with strain-speciﬁc susceptibility to norovirus infec-
tion [7–10].Although most data from ﬁeld studies suggest a pat-
tern of secretor-dependent susceptibility to norovirus infection
[7, 8, 11–13], other studies have shown that secretor-negative in-
dividuals can also be infected [14–19]. Several studies have also
demonstrated that norovirus strains differ in their ability to bind
HBGAs [20–23]. For example, most GII, genotype 4 (GII.4) vi-
ruses bind to secretor-positive individuals from all ABO blood
groups [14]; GI.1 strongly binds secretor-positive individuals
from blood group A, O, and AB [8]; whereas GI, genotype 8
(GI.8) binds saliva from secretor-positive and secretor-negative
individuals [23].
While norovirus is frequently detected in stool samples from
patients with diarrhea, the virus can also be detected in healthy
individuals. Overall, detection rates are approximately 8%
among healthy controls [1],but in some studies, mainly involving
children from low-income countries, norovirus has been nearly
as prevalent, and sometimes more so, in controls than in cases
[24, 25]. Cohort studies may be better suited to understand the
natural history of norovirus infection and shedding in healthy
controls, especially in children in developing countries [24].
In light of the progress of norovirus vaccine development
[26], it is becoming critically important to characterize the in-
cidence of endemic, community-acquired norovirus and the ac-
quisition of natural immunity against norovirus infection and
diarrhea. In this study, we followed a community-based birth
cohort in a rural district in Ecuador with the aim to estimate
(1) the incidence of norovirus gastroenteritis from birth to 3
years of age, (2) the protective effect of norovirus infection
against subsequent infection and disease, and (3) the associa-
tion of infection and disease with FUT2 secretor status.
METHODS
Ethics Statement
The study was approved by institutional review boards of Pon-
tiﬁcia Universidad Catolica del Ecuador (Quito, Ecuador) and
the Centers for Disease Control and Prevention (Atlanta,
Georgia). Written informed consent was obtained from each
child’s parent or guardian.
Study Design, Recruitment, and Data Collection
The study was conducted in Quinindé, a town in Esmeraldas
Province in tropical, coastal Ecuador. A diarrhea surveillance
cohort of 194 children was recruited between March and
December 2009 from within a birth cohort, the ECUAVIDA co-
hort, which is described in detail elsewhere [27]. Brieﬂy, the co-
hort of 2404 children from the District of Quinindé was
recruited around the time of birth at the public hospital (Hos-
pital Padre Alberto Buffoni [HPAB]) in Quinindé between No-
vember 2006 and December 2009. A subset of the larger cohort
was included in a group monitored under diarrhea surveillance:
children entering the birth cohort between March 2009 and De-
cember 2009 who lived within the municipal boundaries of
Quinindé were enrolled for the surveillance study and were fol-
lowed up to 3 years of age. Inclusion criteria into the surveil-
lance study were as follows: (1) healthy and aged <14 days,
(2) maternal stool sample availability, (3) maternal age of ≥17
years, and (4) residence in Quinindé. Routine telephone calls
were made twice weekly to mothers to determine whether the
child in the surveillance sample had diarrhea, and medical
records of visits to the cohort pediatric clinic at HPAB were col-
lected. All families were advised on the importance of surveil-
lance and were asked to report all cases of diarrhea to the clinic
or directly to the study coordinator in Quinindé. During each
telephone call, the mother or caregiver was also asked about
any illness at present; respiratory symptoms, fever, diarrhea, or
other signs or symptoms in the child or other members of the
household were recorded. If diarrhea was reported, the family
was asked to take the child to the clinic the same day for assess-
ment of severity, treatment, and collection of a stool specimen.
If this was not possible, a physician visited the child’s house for
evaluation and sample collection either the same day or the next
day. Stool collection from asymptomatic children occurred
during routine home visits at ages 7, 13, 24, and 36 months
and during routine clinic visits at ages 3, 18, and 30 months.
A child was considered asymptomatic if they did not have diar-
rhea for at least 2 weeks before the routine home visit. During
home visits at ages 7, 13, 24, and 36 months, child length/height
(measured using infantometers/stadiometers) and weight
(measured using digital pediatric scales) were recorded.
Norovirus Testing
All collected stool samples were aliquoted into 2-mL tubes at
the FEPIS laboratory in Quinindé and stored at 4°C. RNA ex-
traction was done using the Qiagen QIAamp Viral RNA Mini
Kit, and extracted RNA was stored at −20°C prior to analysis.
Real-time reverse transcription polymerase chain reaction
(RT-qPCR) was used to detect GI and GII norovirus RNA
[28]. All cycle threshold (Ct) values of <40 were considered
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positive; we also repeated all analysis with Ct cutoffs of <35 for
GI viruses or <37 for GII viruses. The latter approach reduced
the overall rates of infection but did not affect any of the pat-
terns or observed associations (data not shown). Positive sam-
ples were genotyped by sequence analysis [29].
Deﬁnitions
A diarrhea sample was deﬁned as a stool sample obtained from
a child who had ≥3 liquid or semiliquid stools in 24 hours, with
a time of collection of <14 days before the telephone call or con-
sultation with the clinic/hospital. When a child presented to the
clinic with diarrhea, stool samples and clinical data were collect-
ed after physician evaluation. Norovirus diarrhea was consid-
ered an episode of diarrhea in which norovirus RNA was
detected in stool by RT-qPCR. Asymptomatic norovirus infec-
tion was deﬁned as a stool sample from an asymptomatic child
in which norovirus was detected.
Blood Group and Secretor Genotyping
ABO blood group determination of capillary blood samples was
done by agglutination with standard antisera. To ascertain se-
cretor status, saliva samples were collected from children >3
years of age into Oragene Discover OG575 kits (DNA Genotek,
Canada), and DNAwas extracted by following the manufactur-
er’s instructions. Secretor status genotyping was determined by
PCR ampliﬁcation and pyrosequencing of FUT2 at nucleotide
428 (G>A) as previously described [6].
Statistical Analysis
The prevalence and 95% conﬁdence intervals (CIs) of norovirus
infection among diarrhea cases and asymptomatic control sam-
ples was estimated according to a binomial distribution. We cal-
culated the cumulative incidence of diarrhea, norovirus infection,
and disease by Kaplan–Meier survival analysis. Cumulative inci-
dence estimates were generated at 12, 24, and 36 month of age.
The follow-up time for an individual child was divided ac-
cording to the number of previous infections. For example,
the period between birth and ﬁrst infection was identiﬁed as
0 previous infections and the period between ﬁrst infection
and second infection was identiﬁed as 1 previous infection.
The number of previous infections was then modeled as a
time-varying covariate. To examine the association of previous
infection episodes, individual-level, and family-level character-
istics with norovirus infection and disease risk, we ﬁtted multi-
level mixed-effect Poisson regression models. The individual
child (with multiple observation periods) was considered the
level for the random effect under the assumption of indepen-
dent covariance. We calculated P values for associations with
norovirus infection and disease rates and genogroup-speciﬁc in-
fection rates by the Wald test. All regression analyses were con-
trolled for age (in 6-month intervals up to 1 year and in yearly
intervals thereafter) and sex.
RESULTS
Recruitment and Characteristics of Surveillance Cohort
A total of 194 children were recruited and followed up in the sur-
veillance cohort. The 194 children were followed for 206 658
person-days. The range of follow-up was 211–1305 days, with
>90% of children followed for at least 2 years. The numbers of
children followed to at least 6 months, 1 year, 2 years, and 3 years
of age were 194 (100%), 193 (>99%), 183 (94%), and 135 (70%),
respectively. A total of 151 children (77%) were recruited on the
ﬁrst day of life, and all were recruited before day 14 of age. Rel-
evant characteristics of study children, their mothers, and their
living environment are provided in Table 1. All children lived in
an urban environment in the town of Quinindé and tended to
Table 1. Characteristics of Surveillance Birth Cohort (N = 194)
Characteristic Individuals, Percentage (No.)
Mother
Age, y, median 24
Education level
Incomplete primary 11 (21)
Complete primary 59 (114)
Complete secondary 30 (59)
Household
Socioeconomic status
Low 17 (33)
Medium 33 (65)
High 50 (96)
No. of other children
0 29 (56)
1 26 (50)
≥2 45 (88)
Child
Sex
Female 54 (105)
Male 46 (89)
Birth weight, g
<3300 47 (92)
≥3300 53 (102)
Breast-feeding duration, mo
0–6 16 (31)
7–12 39 (75)
≥13 45 (85)
Secretor status
Positive 88 (157)
Negative 12 (21)
Blood group
O 62 (111)
A 20 (35)
B 16 (29)
AB 2 (3)
Data on breast-feeding duration were missing for 3 children, and data on
secretor status and blood group were missing for 16 children.
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be of higher socioeconomic level than the cohort in general
(50% were deﬁned as being in the high socioeconomic tertile).
A high proportion of children lived in a household with at least
2 other children of households (88 [45%]) and had a ﬂushing
toilet (122 [63%]), but relatively few had access to potable
piped water (25 [13%]). Blood group and secretor genotypes
were determined at 3 years of age in 178 children (92%; Table 1):
most children (111 [62%]) were blood group O, and 158 (88%)
were secretor positive. The proportions, by FUT2 genotype,
were as follows: SeSe (homozygote secretor-positive children),
79 (44%); Sese428 (heterozygote secretor-negative children):
79 (44%), and se428se428 (homozygote secretor negative chil-
dren): 21 (12%).
Over the 3-year study period, 1454 stool samples were col-
lected, of which 438 (30%) were collected during an episode
of acute diarrhea, while 1016 (70%) samples were collected
from children without diarrheal symptoms for at least 14
days. There was a median of 7 samples (range, 1–20 samples)
collected per child. There were no major demographic differ-
ences in children with ≥7 samples collected, compared with
those with <7 samples collected, with the exception of children
with older mothers, who had fewer samples collected (P = .008).
Diarrhea and Norovirus Infections
Over the 3-year period, we detected a mean (±SD) of 2.26 ± 2.30
diarrheal cases per child (range, 0–12 cases): 44 children (23%)
had 0 episodes of diarrhea, 85 (44%) had 1–2 episodes, 50
(26%) had 3–5 episodes, and 15 (8%) had >5 episodes. The
cumulative incidence of diarrhea in the surveillance cohort,
by number of episodes over the 36 months of follow-up, is
shown in Figure 1A.
Norovirus was detected in 260 samples (18%) but was not
found more frequently in diarrheal samples (79 of 438 [18%])
than in routine samples (181 of 1016 [18%]; P = .919). This pat-
tern did not appear to differ by age (Figure 2). However, when
norovirus was detected, viral loads (based on Ct values) were
higher in diarrheal samples (median Ct value, 28.02), compared
with routine samples (median Ct value, 32.2; P = .005 by the
Wilcoxon rank sum test; data not shown).
Sixty-six percent of children had at least 1 documented infec-
tion (with or without symptoms) with norovirus during the ﬁrst
3 years of life, 40% of children had 2 infections, but few (16%)
had >2 infections (Figure 1B). At least 1 episode of norovirus-
associated diarrhea was observed in 30% of children (59), but
relatively few (10%) had >1 episode (Figure 1C). Overall, noro-
virus infection and disease was detected at rates of 51 cases per
Figure 2. Norovirus detection among asymptomatic routine and diar-
rheal stool samples, by age.
Figure 1. Cumulative incidence of diarrhea (A), norovirus infection (B),
and norovirus diarrhea (C) from birth to age 36 months. First event, black;
second event, red; third event, green; fourth event, blue; and ﬁfth event,
orange.
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Table 2. Association Between Previous Infections, Sociodemographic Characteristics, and Host Characteristics and Norovirus Infection
and Disease Risk
Variable
Infection Disease
No. Ratea RR (95% CI)b P Value No. Ratea RR (95% CI)b P Value
No. of previous norovirus infections
0 130 43.5 Reference 40 13.4 Reference
1 79 71.5 1.01 (.51–1.99) .972 30 27.1 1.88 (1.11–3.21) .019
≥2 43 51.9 0.82 (.26–2.52) .422 13 15.7 1.19 (.50–2.90) .692
No. of previous genogroup I infections
0 190 47.6 Reference 62 15.5 Reference
≥1 62 66.6 1.21 (.90–1.63) .204 21 22.6 1.51 (.84–2.74) .170
No. of previous genogroup II infections
0 161 47.7 Reference 52 15.4 Reference
≥1 91 58.7 0.92 (.60–1.42) .721 31 20.0 1.24 (.71–2.18) .450
Age, mo
0–5 5 5.2 Reference 3 3.1 Reference
6–11 73 75.7 14.65 (5.92–36.24) <.001 34 35.3 11.34 (3.49–37.01) <.001
12–23 117 63.8 12.35 (5.05–30.23) <.001 38 20.7 6.66 (2.06–21.59) .002
24–36 57 49.1 9.50 (3.81–23.71) <.001 8 6.9 2.16 (.57–8.17) .243
Sex
Male 106 46.1 Reference 28 12.2 Reference
Female 146 55.5 1.20 (.93–1.55) .153 55 20.9 1.68 (1.03–2.77) .039
Socioeconomic status
Low 32 39.1 Reference 10 12.2 Reference
Medium 78 46.4 1.17 (.78–1.78) .440 25 14.9 1.23 (.56–2.70) .611
High 142 58.5 1.47 (1.00–2.17) .049 48 19.8 1.60 (.77–3.33) .208
No. of other children in household
0 72 51.3 Reference 21 15.0 Reference
1 58 45.5 0.89 (.63–1.27) .537 19 14.9 1.04 (.51–1.95) .902
≥2 122 54.3 1.02 (.76–1.38) .885 43 19.1 1.21 (.72–2.77) .505
Maternal education level
Incomplete primary 19 36.2 Reference 6 11.4 Reference
Complete primary 150 51.3 1.34 (.83–2.19) .235 55 18.8 1.50 (.60–3.75) .386
Complete secondary 83 56.1 1.52 (.91–2.52) .106 22 14.9 1.24 (.47–3.31) .655
Season
Dry (July to Nov) 132 54.1 Reference 32 13.1 Reference
Wet (Dec to Jun) 120 48.2 0.72 (.56–.93) .012 51 20.5 1.36 (.87–2.16) .179
Secretor status
Negative 24 45.9 Reference 8 15.3 Reference
Positive 216 52.8 1.15 (.75–1.77) .522 71 17.4 1.20 (.53–2.71) .655
Secretor genotype
Not applicablec 24 45.9 Reference 8 15.3 Reference
Heterozygous 104 50.4 1.09 (.70–1.71) .703 27 13.1 0.89 (.37–2.09) .793
Homozygous 112 55.2 1.21 (.77–1.90) .402 44 21.7 1.51 (.66–3.47) .328
Blood group
O 149 52.1 Reference 47 16.4 Reference
A 47 52.5 0.99 (.71–1.40) .992 10 11.2 0.65 (.31–1.36) .259
B 40 51.4 0.96 (.67–1.37) .806 21 27.0 1.59 (.89–2.86) .116
A/B 4 50.8 1.07 (.38–2.97) .900 1 12.5 1.06 (.12–9.15) .952
Abbreviations: CI, confidence interval; RR, relative risk.
a Per 100 person-years.
b All models include age and sex as controlling covariates.
c Data are for secretor-negative children.
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100 person-years (95% CI, 45–58) and 17 cases per 100 person-
years (95% CI, 14–21), respectively.
Age was an important determinant of the risk of norovirus
infections (Table 2): the peak incidence of norovirus infections,
76 infections per 100 person-years, was observed between 6 and
11 months of age, declining to 9.5 infections per 100 person-
years at 24–36 months of age (Table 2). The associations
between risk of norovirus infection or norovirus diarrhea and
previous norovirus infections, sociodemographic factors, and
individual characteristics are shown in Table 2. The only factor
associated with the incidence of norovirus infections was sea-
son, with higher rates of infection during the dry months of
July through November (P = .012). Previous norovirus infec-
tions were not signiﬁcantly associated with the risk of subse-
quent norovirus infection.
The incidence of norovirus diarrhea was strongly dependent
on age, with a peak at 6–11 months of age of 35.3 episodes per
100 person-years. Norovirus diarrhea incidence was more fre-
quent among females (P = .039) but was not signiﬁcantly asso-
ciated with secretor status or genotype. Having one previously
documented norovirus infection was positively associated with
the risk of norovirus diarrhea, although the same effect was not
observed for ≥2 previous infections.
Norovirus Genotype Distribution
A total of 154 samples (61%) were GII positive, 85 (34%) were
GI positive, and 13 (5.2%) had GI/GII mixed infections. Factors
associated with incidence of infection with GI and GII norovi-
rus are shown in Tables 3 and 4. There was a tendency for high-
er risk among secretor-positive children for GII infection
(although the difference was not statistically signiﬁcant) but
no apparent association with GI, after control for age and sex.
Similarly, previous norovirus infections, regardless of gen-
ogroup, were not associated with the incidence of subsequent
Table 3. Association Between Previous Infections, Sociodemographic Characteristics, and Host Characteristics and Norovirus
Genogroup I and II Infection Risk
Variable
Genogroup I Genogroup II
No. Ratea RR (95% CI)b P Value No. Ratea RR (95% CI)b P Value
No. of previous norovirus infection
0 47 15.7 Reference 90 30.1 Reference
1 36 31.7 1.54 (.95–2.47) .074 49 44.3 1.15 (.80–1.65) .432
≥2 16 19.3 1.01 (.45–2.24) .973 28 33.7 0.92 (.58–1.46) .730
No. of previous genogroup I infection
0 75 18.8 Reference 124 31.0 Reference
≥1 23 24.7 1.12 (.69–1.83) .623 43 46.2 1.31 (.91–1.89) .139
No. of previous genogroup II infection
0 61 18.1 Reference 110 32.6 Reference
≥1 37 23.8 1.07 (.70–1.67) .731 57 37.8 0.81 (.39–1.69) .584
Season
Dry (July to Nov) 37 15.1 Reference 99 40.6 Reference 37
Wet (Dec to Jun) 61 24.5 1.38 (.86–1.98) .204 68 27.3 0.55 (.40–.75) <.001
Secretor status
Negative 12 22.9 Reference 12 22.9 Reference
Positive 82 20.1 0.87 (.46–1.65) .658 147 35.9 1.56 (.86–2.82) .135
Secretor genotype
Not applicablec 12 22.9 Reference 12 22.9 Reference
Heterozygous 41 19.8 0.86 (.45–1.65) .658 69 33.5 1.45 (.79–2.68) .232
Homozygous 41 20.2 0.88 (.46–1.69) .702 78 38.5 1.68 (.92–3.09) .094
Blood group
O 60 21.0 Reference 95 33.2 Reference
A 17 18.9 0.90 (.52–1.54) .692 32 35.7 1.07 (.71–1.59) .753
B 15 11.6 0.90 (.51–1.59) .826 29 37.2 1.10 (.72–1.69) .658
A/B 2 6.2 1.27 (.30–5.37) .742 3 37.6 1.22 (.38–3.90) .737
Abbreviations: CI, confidence interval; RR, relative risk.
a Per 100 person-years.
b All models include age and sex as controlling covariates.
c Data are for secretor-negative children.
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infection. The only factor associated with infection was the
reduced incidence of GII infections observed during the wet
season (December through June; P < .001). An association in
the opposite direction was observed for GI, but this was
nonsigniﬁcant.
We were able to determine the genotype for 106 samples
(Figure 3). The most common genotype was GII.4 (27 infec-
tions [25%]), followed by GII.1 (20 [19%]), GI.3 (9 [8%]),
GII.2 (11 [10%]), and a tentative new GII genotype (GII.23;
6 [6%]). We observed 12 GI/GII mixed infections (11%), in-
cluding 4 due to GII.4 (4%). Among the GII.4-positive samples
(including those from mixed infections), the following variants
were observed: New Orleans 2009, 21 samples; Den Haag 2006,
5; Sydney 2012, 4; and Osaka 2008, 1. The genotype distribution
among diarrheal stools and healthy stools was similar.
All 27 GII.4 single infections and all 4 coinfections that were
positive for GII.4 were in secretor-positive children (relative
risk [RR], undetermined; P < .001 for both comparisons;
Tables 3 and 4). We observed a nonsigniﬁcantly lower rate
of GII infection (excluding GII.4; RR, 0.69; 95% CI, .3–1.2)
and GI infection (RR, 0.61; 95% CI, .2–1.7) among secretor-
positive children. However, when combining all non-GII.4
noroviruses, the rates of infection were signiﬁcantly lower
among secretor-positive children, compared with secretor-
negative children (RR, 0.56; 95% CI, .3–.9; P = .023). We also
detected a tentative new GII genotype (GII.23); all 6 positive
Table 4. Norovirus Genotype–Speciﬁc Rates of Infection for Secretor-Negative and Secretor-Positive Children
Variable
Secretor Negative Secretor Positive
RR (95% CI)b P ValuesInfections, No. Ratea Infections, No. Ratea
GI 4 7.6 18 4.4 0.61 (.21–1.70) .342
GII (excluding GII.4) 7 13.4 38 9.0 0.69 (.31–1.15) .358
GII.1 5 9.6 17 4.2 0.43 (.15–1.21) .111
GII (untypeable) 0 0 6 1.5 Undetermined <.001
GI/GII mixed (excluding GII.4) 3 5.7 4 1.0 0.19 (.05–.80) .024
Non-GII.4 (combined) 14 26.8 59 14.4 0.56 (.34–.94) .029
GII.4 (single infections) 0 0 27 6.6 Undetermined <.001
GII.4 (including GI mixed) 0 0 31 7.6 Undetermined <.001
GI/GII mixed (including GII.4) 0 0 4 1.0 Undetermined <.001
Abbreviations: CI, confidence interval; GI, genogroup I; GII, genogroup II; GII.1, genogroup II, genotype 1; GII.4, genogroup 2, genotype 4; RR, relative risk.
a Per 100 person-years.
b All models include age and sex as controlling covariates.
Figure 3. Norovirus genotype distribution of infections in secretor-negative (A) and secretor-positive (B) children. Abbreviation: G, genogroup.
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samples were detected in secretor-positive children (RR,
undermined; P < .001).
DISCUSSION
With 60% of children having at least 1 infection (symptomatic
or asymptomatic) and 30% at least 1 norovirus-associated diar-
rhea episode within the ﬁrst 3 years of life, this study conﬁrms
the high incidence of norovirus infection in children that has
been found by many studies worldwide [1, 4, 30]. Our results
were not consistent with the notion of acquired immunity to
norovirus, whereby each infection would be expected to provide
a degree of protection against the next. Nor did we ﬁnd evidence
that immunity is genogroup speciﬁc: rates of GI or GII infections
did not decrease following previous infection(s) with the same
genogroup. Overall, the rates of norovirus infection and disease
were similar among secretor-positive and secretor-negative chil-
dren, but the genotypes causing infections differed markedly. All
GII.4 infections were among secretor-positive individuals.
Our ﬁndings contrast, to some extent, with those of a recent
birth cohort study from neighboring Peru [4]. Saito et al found
roughly similar rates of norovirus infection and disease that we
found, but they observed a modest reduction in infection and
disease rates in children with previous infections. Saito et al test-
ed routine samples more frequently, at least in the ﬁrst year of
life, when monthly samples were tested, which means they had a
more complete capture of asymptomatic infections. Field work-
ers also visited each household twice weekly, so they may have
had more-complete capture of diarrhea episodes.
Our study is consistent with volunteer challenge studies and
observational studies demonstrating that secretor-negative indi-
viduals have near-complete resistance to GII.4 infection [15,
31], as well as to GI.I. infection [8, 10] and a new GII genotype
described in this study. GII.4 noroviruses can also infect secre-
tor-negative individuals, suggesting a lack of complete resistance
to disease [16]. This is in agreement with a recent study that
suggests that most recent GII.4 variants are able to bind Lewis
glycans from secretor-negative individuals [14]. Challenge stud-
ies with norovirus GII.2 showed that 33% of secretor-negative
individuals were infected [17]. Moreover, other studies have
shown that GI.3 noroviruses can infect independently of secretor
status of the host [18, 19].Resistance to infection among secretor-
negative individuals has been demonstrated mainly for GI.1 and
GII.4 [8, 10, 15], with an apparent lack of association for GII.3
[31] or GII.2 [11]; few data exist for other genotypes.
An unexpected ﬁnding of our study was that the rate of non-
GII.4 infection was nearly double among secretor-negative chil-
dren. Therefore, overall, rates of disease were the nearly same
among secretor-positive and secretor-negative children. We
are not aware of any previous data suggesting a heightened
risk of infection for secretor-negative individuals. It is possible
that non-GII.4 viruses bind to currently unknown ligands in
secretor-negative individuals. Another hypothesis is that GII.4
infection confers some degree of heterotypic immunity to sub-
sequent infection with non-GII.4 viruses. However, our sample
size was too small to test this hypothesis.
Birth cohort studies can be instrumental in gaining under-
standing of the acquisition of immunity to childhood infections
[32, 33], and we have advocated for such study designs for nor-
ovirus [34]. So why did we not observe patterns consistent with
the acquisition of immunity? A weakness of our study was the
relatively infrequent collection of routine stool samples from
healthy children. We collected a routine stool sample approxi-
mately every 6 months. With duration of shedding typically
lasting <1 month, more-frequent sampling would result in de-
tection of more infections, so it is likely that substantial num-
bers of asymptomatic infections were missed. Although there
were extended periods when some children were temporarily
lost to follow-up, excluding these periods from analyses did not
appreciably change our results (data not shown), but this leaves
open the possibility that substantial numbers of symptomatic
infections were missed. Underascertainment in our cohort is a
possible explanation for our negative ﬁndings: we measured a
diarrhea incidence of <1 episode per child-year, compared
with an estimate of 4.0 episodes per child-year based on a sys-
tematic review of 29 studies from the Americas [35].
In summary, our study suggests a high incidence of norovirus
infection and disease in Ecuadorian children, but we did not
ﬁnd clear evidence for acquired immunity. Secretor-negative in-
dividuals were completely protected against GII.4 viruses, as
well as a tentative new GII genotype, and they had higher rates
of infection with non-GII viruses. Taken together, these ﬁnd-
ings point to a more complicated relationship between host ge-
netics and pathogen than previous described, with GII.4 being
more common and other viruses being less common among se-
cretor-positive individuals.
Future studies may require more-frequent sampling of
asymptomatic infections, longer follow-up, and larger sample
sizes to improve our understanding of the acquisition of immu-
nity and empirical estimates of the duration of protection, if
such protection truly exists. Because our understanding of nor-
ovirus immunity comes mainly from controlled clinical trials
rather than from observational studies in the ﬁeld, it is possible
that natural infection may differ in a number of ways, including
exposure frequency, patient age, exposure dose, and norovirus
genotype. Much larger studies will be required to explore nor-
ovirus genotype–speciﬁc immunity. As such, further observa-
tional ﬁeld studies are necessary to understand both naturally
acquired and vaccine-acquired immunity.
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